Cel-Sci (CVM) AI Stock Analysis

• Market Cap: $71.54M
• Dividend Yield: N/A
• Average Volume (3M): 256.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: N/A
• EPS Growth: 42.29%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.36
• Shares Outstanding: 7,993,356
• 10 Day Avg. Volume: 161,961
• 30 Day Avg. Volume: 256,602
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 2.97
• Enterprise Value/Gross Profit: -4.51
• Enterprise Value/Ebitda: -0.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 27 Underperform
• Price Target: ―

Cel-Sci's stock is significantly impacted by poor financial performance, with persistent losses and negative cash flows being major concerns. Technical analysis shows some positive momentum but is offset by the stock trading below key moving averages. The valuation is challenging due to ongoing losses, making the stock less attractive for investors seeking stable returns.

Cel-Sci Business Overview & Revenue Model

Company Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

How the Company Makes Money

CEL-SCI Corporation primarily makes money through the development and potential commercialization of its lead product candidate, Multikine. The company aims to generate revenue from the eventual sale of Multikine, contingent upon successful clinical trials and regulatory approval. CEL-SCI may also seek revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships could involve sharing research, development costs, and profits from Multikine's commercialization. Additionally, CEL-SCI might receive funding through grants, investor funding, or other financing activities to support its research and development efforts.

Cel-Sci Financial Statement Overview

Summary

Cel-Sci is struggling financially, characterized by a lack of revenue generation, high operational losses, and dependency on external financing. The company's financial health is concerning, with persistent negative cash flows and significant debt levels posing risks to its sustainability.

Income Statement

Cel-Sci has consistently reported zero revenue over the past years, indicating a lack of product commercialization or sales. The gross profit and net income remain negative, reflecting ongoing operational losses and high costs relative to revenue. The company also faces negative EBIT and EBITDA margins, highlighting inefficiencies and challenges in achieving profitability.

Balance Sheet

The company's financial leverage is relatively high, as indicated by the debt-to-equity ratio, due to significant debt levels compared to equity. Stockholders' equity has been declining, with the equity ratio showing a downward trend. This reflects potential balance sheet risks, including financial instability and limited flexibility for future financing.

Cash Flow

Cel-Sci is experiencing negative operating and free cash flows, suggesting challenges in generating cash from operations. The company relies heavily on financing activities to fund operations, which may not be sustainable in the long term. The operating cash flow to net income ratio is unfavorable, indicating inefficiencies in cash generation relative to reported losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.95M	0.00	0.00	0.00	0.00	558.66K
Gross Profit	-3.92M	-3.97M	-3.96M	-3.88M	-499.00K	540.82K
EBITDA	-20.81M	-22.21M	-29.32M	-31.74M	-33.96M	-26.83M
Net Income	-25.42M	-26.92M	―	-38.27M	-39.19M	-32.22M
Balance Sheet
Total Assets	20.34M	26.99M	30.53M	50.52M	75.87M	40.54M
Cash, Cash Equivalents and Short-Term Investments	1.79M	4.74M	4.15M	22.67M	42.21M	15.51M
Total Debt	9.96M	11.62M	13.57M	15.30M	15.97M	13.94M
Total Liabilities	13.31M	14.12M	17.31M	18.36M	19.34M	20.81M
Stockholders Equity	7.02M	12.87M	13.21M	32.16M	56.53M	19.73M
Cash Flow
Free Cash Flow	-17.32M	-18.91M	-23.22M	-18.90M	-27.83M	-17.97M
Operating Cash Flow	-17.27M	-18.81M	-22.85M	-18.24M	-18.79M	-15.28M
Investing Cash Flow	-52.71K	-108.09K	-372.26K	5.49M	-15.18M	-2.69M
Financing Cash Flow	18.73M	19.51M	4.69M	-638.43K	54.52M	25.04M

Cel-Sci Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVM, the sentiment is Positive. The current price of 8.95 is below the 20-day moving average (MA) of 9.84, above the 50-day MA of 8.91, and above the 200-day MA of 8.85, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 20.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVM.

Cel-Sci Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	54 Neutral	123.02M	-3.22	-38.74%	―	1071.91%	-27.61%
PULM	53 Neutral	16.18M	-2.04	―	―	-96.76%	26.87%
NNVC	42 Neutral	22.82M	-2.03	―	―	―	13.83%
ENLV	36 Underperform	24.57M	-1.82	―	―	―	52.51%
CVM	27 Underperform	$71.54M	―	-328.04%	―	―	42.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%